New Clinical Data Shows AMS’ Minimally Invasive Treatment Options Effective at Restoring Female Pelvic Health

Tue, 29 Sep 2009 16:14:00 0500

MINNETONKA, Minn.-(Business Wire)-September 29, 2009 -

ImThera Medical to Begin European Clinical Trials in Belgium

Tue, 29 Sep 2009 14:00:00 0500

SAN DIEGO-(Business Wire)-September 29, 2009 - ImThera Medical, Inc. has received Ethics Committee clearance to begin human clinical trials in Belgium. The trials will include ImThera’s Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy to treat Obstructive Sleep Apnea (OSA). Along...

Luminex Corporation Hosts Seventh Annual Planet xMAP Europe

Tue, 29 Sep 2009 14:00:00 0500

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it will host Planet xMAP Europe 2009, its annual European multiplexing technology symposium, October 7-8, 2009, at Beurs van Berlage in Amsterdam. The program for...

Bio Japan 2009: The Biggest Biotechnology Event in Japan.

Tue, 29 Sep 2009 13:07:00 0500

YOKOHAMA, Japan-(Business Wire)-September 29, 2009 - We would like to thank you sincerely for your understanding and ongoing cooperation for BioJapn.

With your wholehearted support, BioJapan has been progressing successfully in both its contents and scale every year...

Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma

Tue, 29 Sep 2009 13:00:00 0500

BERKELEY, Calif.-(Business Wire)-September 29, 2009 - Plexxikon Inc. announces that enrollment has been initiated and the first patient has been treated in the first of two pivotal trials of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly selective...

Sermo Panels Tap into Social Media Platform for On-Demand Physician Opinions

Tue, 29 Sep 2009 13:00:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 29, 2009 - Sermo, the largest online community exclusively for physicians, today formally launched Sermo Panels™ - a new on-demand offering enabling businesses to engage with and gather insights from physicians in a private online workspace. Sermo...

SFC Fluidics, LLC Receives Funding from US Army for Development of Traumatic Brain Injury Diagnostic Device

Tue, 29 Sep 2009 12:30:00 0500

FAYETTEVILLE, Ark.-(Business Wire)-September 29, 2009 - SFC Fluidics, LLC recently announced it has received a...

Cerus to Present Proposal for INTERCEPT Platelet US Phase III Clinical Trial at November BPAC Meeting

Tue, 29 Sep 2009 12:30:00 0500

CONCORD, Calif.-(Business Wire)-September 29, 2009 - Cerus Corporation (NASDAQ:CERS) announced today that it will present the proposed design for a U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets at the upcoming November meeting of the FDA's Blood Products Advisory...

BSD Medical Corporation Sells Hyperthermia System to University of California, San Francisco Medical Center

Tue, 29 Sep 2009 12:00:00 0500

SALT LAKE CITY-(Business Wire)-September 29, 2009 - BSD Medical Corporation (NASDAQ: BSDM) (

BioClinica™ Showcases Clinical Data Management at SCDM Annual Conference

Tue, 29 Sep 2009 10:00:00 0500

NEWTOWN, Pa.-(Business Wire)-September 29, 2009 - BioClinica, Inc., (NASDAQ: BIOC) a leading global provider of clinical trial services, is helping to advance the discipline of clinical data management and will demonstrate integrated eClinical and imaging data management technology and...

Flexible Stenting Solutions, Inc. Receives Conditional IDE Approval for FlexStent® Femoropopliteal Self Expanding Stent System

Mon, 28 Sep 2009 21:56:00 0500

EATONTOWN, N.J.-(Business Wire)-September 28, 2009 - Flexible Stenting Solutions Inc. (“FSS”), a leading developer of next generation peripheral arterial and biliary stents, announced today that it has received Conditional Investigational Device Exemption (IDE) approval for its...

Maxygen Announces Management Changes

Mon, 28 Sep 2009 20:05:00 0500

REDWOOD CITY, Calif.-(Business Wire)-September 28, 2009 - Maxygen, Inc. (Nasdaq:MAXY) announced today that James Sulat, who currently serves as a director of the company, has been appointed to serve as Maxygen’s Chief Executive Officer, effective October 1, 2009. Mr. Sulat will replace...

Burzynski Research Institute Signs Research Agreement with the University of Alabama at Birmingham (UAB), Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility

Mon, 28 Sep 2009 19:14:00 0500

HOUSTON-(Business Wire)-September 28, 2009 - The Burzynski Research Institute, Inc. (BRI) today announced that it has signed a Research Agreement with the UAB Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data...

International Medica Foundation Starts Phase II Clinical Trial for Rotavirus Vaccine

Mon, 28 Sep 2009 16:03:00 0500

ROCHESTER, Minn.-(Business Wire)-September 28, 2009 - More than half a million children – or 1,400 to 1,600 each day – die from rotavirus, the most common cause of severe childhood diarrhea. Almost all of these deaths occur in developing countries, where lifesaving medical care may not be...

DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs

Mon, 28 Sep 2009 15:00:00 0500

BIRMINGHAM, Ala.-(Business Wire)-September 28, 2009 - DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development...

Savvion and Patni Announce Strategic Partnership

Mon, 28 Sep 2009 14:00:00 0500

SANTA CLARA, Calif.-(Business Wire)-September 28, 2009 - Savvion® and Patni Life Sciences announced today a strategic...

Biomagnetics Diagnostics Receives a Financing Commitment up to $1 Million to Speed Development of Malaria Testing Technology

Mon, 28 Sep 2009 13:30:00 0500

GENEVA-(Business Wire)-September 28, 2009 - Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced it has received a equity-based financing commitment up to $1 million...

Ligand and GlaxoSmithKline Collaboration Identifies New Compound

Mon, 28 Sep 2009 12:36:00 0500

SAN DIEGO-(Business Wire)-September 28, 2009 - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline (NYSE:GSK), GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that...

PolyMedix Receives U.S. Patent Protection for Licensed Computational Methods to Design Antimicrobial Polymers

Mon, 28 Sep 2009 12:26:00 0500

RADNOR, Pa.-(Business Wire)-September 28, 2009 - PolyMedix, Inc. (OTC BB: PYMX, febit holding GmbH

Thommen Medical Announces Chairside Implant Conditioning – North American Premiere at the 2009 AAOMS Meeting in Toronto, Canada

Mon, 28 Sep 2009 09:00:00 0500

CLEVELAND-(Business Wire)-September 28, 2009 - Thommen Medical, a leading Swiss company in the area of the oral implantology, will officially launch the latest products in the evolution of implant surface technology, APLIQUIQ and INICELL, at the 2009 AAOMS Meeting in Toronto, Canada...

Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin)

Fri, 25 Sep 2009 16:37:00 0500

WHITEHOUSE STATION, N.J.-(Business Wire)-September 25, 2009 - Merck & Co., Inc., issued the following statement today in response to the U.S. Food and Drug Administration's (FDA's) update on JANUVIA (sitagliptin) and JANUMET (sitagliptin/metformin).

"Merck has thoroughly...

Quintiles and Allergan Announce Co-Promotion for Sanctura XR®

Fri, 25 Sep 2009 13:00:00 0500

RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 25, 2009 - Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR^® (trospium chloride extended release capsules), an...

Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma

Fri, 25 Sep 2009 13:00:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced the presentation of final data from a clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as monotherapy in patients with Renal Cell Carcinoma (RCC). The...

Advaxis Secures $5.0 Million Investment

Fri, 25 Sep 2009 12:30:00 0500

NORTH BRUNSWICK, N.J.-(Business Wire)-September 25, 2009 - Advaxis, Inc. (OTCBB: ADXS), has entered into a definitive agreement for a $5 million investment commitment (the “Investment”) with an investment fund (the “Investor”).

“This financing, combined with...

EnzymeRx Announces Its IND for Uricase-PEG 20 Becomes Effective

Fri, 25 Sep 2009 12:10:00 0500

PARAMUS, N.J.-(Business Wire)-September 25, 2009 - EnzymeRx, LLC (www.enzymerx.com), a...

Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801

Fri, 25 Sep 2009 12:00:00 0500

MIRAMAR, Fla.-(Business Wire)-September 25, 2009 - Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its...

Diabetes Foot Specialists Say Cost-Effective Wound Therapy Underused Due to Healthcare Reimbursement Incentives

Fri, 25 Sep 2009 12:00:00 0500

-(Business Wire)-September 25, 2009 - WHAT: Every 30 seconds, across the globe an individual loses a limb due to poor diabetes management. In the U.S., diabetes affects nearly 24 million people. When poorly controlled, diabetes results in nerve damage and poor circulation to the legs and...

Dyax Corp. to Present at the JMP Securities Healthcare Focus Conference

Fri, 25 Sep 2009 11:30:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 25, 2009 - Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Gustav A. Christensen, President and Chief Executive Officer of Dyax, will present at the Fourth Annual JMP Securities Healthcare...

Reverse Medical Corporation Receives FDA IDE Clinical Study Approval for the ReStoreTM Microcatheter

Thu, 24 Sep 2009 22:56:00 0500

IRVINE, Calif.-(Business Wire)-September 24, 2009 - Reverse Medical Corporation announced today that it has received US Food and Drug Administration (FDA) conditional approval to begin a neurothrombectomy IDE study for its ReStore™ Microcatheter at twenty US centers. The study is planned to...

NEVO™ Sirolimus-Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months Than Taxus® Liberte® Stent

Thu, 24 Sep 2009 22:00:00 0500

SAN FRANCISCO-(Business Wire)-September 24, 2009 - At six months, patients receiving the NEVO^™ Sirolimus-eluting Coronary Stent reported significantly less chest pain (also known as angina) than those receiving the Taxus^® Liberte^® Stent. Patients also reported...

Tryton Medical, Inc. Broadcasts Successful Live Case Using Company’s Side-Branch Stent™ to Definitively Treat Bifurcation Lesions at TCT 2009

Thu, 24 Sep 2009 20:37:00 0500

DURHAM, N.C. & SAN FRANCISCO-(Business Wire)-September 24, 2009 - Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today the transmission of a live satellite feed of a clinical case performed in the United Kingdom to an...

Advaxis Cures Late Form 10-Q Filing

Thu, 24 Sep 2009 19:13:00 0500

NORTH BRUNSWICK, N.J.-(Business Wire)-September 24, 2009 - Advaxis, Inc. (OTCBB: ADXS), the live...

Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting

Thu, 24 Sep 2009 17:54:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 24, 2009 - Vertex Pharmaceuticals Incorporated

Imprime PGG® Named a Top 10 Oncology Drug Candidate for Partnering

Thu, 24 Sep 2009 16:44:00 0500

EAGAN, Minn.-(Business Wire)-September 24, 2009 - Biothera, a privately held biotechnology company, announced today that its lead drug candidate, Imprime PGG^®, has been named one of the Top 10 Most Interesting Oncology Projects Available for Partnering by Windhover...

Inhibitex Regains Compliance with NASDAQ Listing Requirements

Thu, 24 Sep 2009 15:45:00 0500

ATLANTA-(Business Wire)-September 24, 2009 - Inhibitex, Inc. (Nasdaq: INHX) (the “Company”), a biopharmaceutical company focused on developing products to treat serious infectious diseases, announced today that it has received notice from The NASDAQ Stock Market ("Nasdaq") stating...

RegeneRx Biopharmaceuticals to Present Several Papers at Second International Symposium on Thymosins in Health and Disease

Thu, 24 Sep 2009 13:41:00 0500

BETHESDA, Md.-(Business Wire)-September 24, 2009 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (PHT Corporation, the leading provider of Genzyme Corporation (Nasdaq: GENZ) announced today...

Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation

Thu, 24 Sep 2009 12:28:00 0500

BERLIN-(Business Wire)-September 24, 2009 - Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC...

BSD Medical Corporation Files $50 Million Shelf Registration

Thu, 24 Sep 2009 12:00:00 0500

SALT LAKE CITY-(Business Wire)-September 24, 2009 - BSD Medical Corporation (NASDAQ:BSDM) (Fractional Flow Reserve (FFR) vs. Angiography in

PsoriasisDX and HairDX To Present “Pharmacogenomics In Dermatology And Cosmetics” During EADV Congress

Wed, 23 Sep 2009 18:11:00 0500

BERLIN & IRVINE, Calif.-(Business Wire)-September 23, 2009 - A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the...

BioPharm America™ 2009 in San Francisco Sets New Benchmark for Partnering Productivity in the US

Wed, 23 Sep 2009 17:59:00 0500

CARLSBAD, Calif. & SAN FRANCISCO-(Business Wire)-September 23, 2009 - Over 700 leaders from the biotechnology and pharmaceutical industry gathered last week for the 2nd annual BioPharm America™ partnering conference, which saw delegates from 665 companies engage in 1579 one-to-one...

Two Top Heart Surgeons Join Endovalve, Inc., Scientific Advisory Board

Wed, 23 Sep 2009 14:05:00 0500

PRINCETON, N.J.-(Business Wire)-September 23, 2009 - Endovalve, Inc., a cardiovascular device company...

pSivida Anounces New Iluvien® Pilot Study in Patients with Macular Edema Secondary to Retinal Vein Occlusion

Wed, 23 Sep 2009 14:00:00 0500

WATERTOWN, Mass.-(Business Wire)-September 23, 2009 - pSivida Corp. (NASDAQ:PSDV)(ASX:PVA)(FWB:PV3), a leading drug delivery company that has developed two of the only three products approved by the FDA for the long term, sustained release delivery of drug to treat chronic back of the eye...

KIKA Clinical Solutions Announces Veracity™ 3.7, New Version of Advanced EDC Solution for Clinical Trial Management

Wed, 23 Sep 2009 13:35:00 0500

BOSTON & PARIS-(Business Wire)-September 23, 2009 - KIKA Clinical Solutions, the leading...

First-Ever Controlled Pharmacological Study of ADHD in College Students Launched

Wed, 23 Sep 2009 13:30:00 0500

BETHLEHEM, Pa.-(Business Wire)-September 23, 2009 - In an effort to help one of the most under studied groups of sufferers of attention deficit hyperactivity disorder (ADHD), researchers at University of Rhode Island and Lehigh University have kicked off the first-ever controlled...

Abiomed Reports Results from Academic Medical Center’s Three-Year Follow-up of MACH II Trial

Wed, 23 Sep 2009 13:14:00 0500

DANVERS, Mass.-(Business Wire)-September 23, 2009 - Abiomed Inc. (NASDAQ: ABMD), a leading provider of

Merck and QIAGEN Collaborate to Accelerate Access to Cervical Cancer Vaccination and Screening in Developing Countries

Wed, 23 Sep 2009 13:11:00 0500

NEW YORK-(Business Wire)-September 23, 2009 - Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world. This initiative is the first time a...

Genzyme Provides Update on Cerezyme and Fabrazyme Supply

Wed, 23 Sep 2009 12:49:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these...

Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress

Wed, 23 Sep 2009 12:15:00 0500

BERLIN-(Business Wire)-September 23, 2009 - According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, Pluristem Therapeutics Inc. (NasdaqCM: PSTI...

Humedica’s Next-Generation Clinical Informatics Platform Offers Unparalleled Insight across the Health Care Continuum

Wed, 23 Sep 2009 10:30:00 0500

BOSTON-(Business Wire)-September 23, 2009 - Humedica, a next-generation health care informatics company...

Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva® and Avastin® in Non-Small Cell Lung Cancer

Wed, 23 Sep 2009 10:00:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 23, 2009 - Idera Pharmaceuticals (Nasdaq: IDRA) today presented interim data from a phase 1b, single arm clinical trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva^® and Avastin^® in...

Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients

Wed, 23 Sep 2009 09:15:00 0500

BERLIN, Germany & BERKELEY, Calif.-(Business Wire)-September 23, 2009 - Plexxikon Inc. today announced encouraging clinical data from a Phase 1 extension study of PLX4032 (RG7204) in metastatic melanoma patients, which expand the results announced from the initial phase of the study...

BioTime, Inc. to Form Asian Subsidiary

Wed, 23 Sep 2009 03:01:00 0500

BEIJING & ALAMEDA, Calif.-(Business Wire)-September 23, 2009 - BioTime, Inc. (OTCBB:BTIM) announced today that it will organize a new subsidiary, BioTime Asia, Limited, for the purpose of clinically developing and marketing therapeutic stem cell products in the People’s Republic of China...

BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger

Tue, 22 Sep 2009 22:30:00 0500

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 22, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that they have determined the final exchange ratio as 0.1828 in connection with the previously announced...

Transoma Medical Enrolls First Patient in Clinical Study Comparing Use of External Recorders with Implantable Monitors to Track Recurrence of Atrial Fibrillation

Tue, 22 Sep 2009 20:22:00 0500

ST. PAUL, Minn.-(Business Wire)-September 22, 2009 - Transoma Medical, Inc., manufacturer of Sleuth AT^™, the only wireless, automated implantable cardiac monitoring system with programmable and frequent electrocardiogram (ECG) sampling, announced today the first enrollment and...

Top 20 Pharma Firms to Hunt for Deals at BIO-Europe 2009

Tue, 22 Sep 2009 18:37:00 0500

ZURICH & VIENNA-(Business Wire)-September 22, 2009 - In order to seek out new partnering opportunities, the top 20 big pharma companies will be in attendance on November 2–4 in Vienna, Austria for BIO-Europe 2009, the largest dedicated partnering conference in Europe. Teams of scouts from...

Bio-Path Holdings, Inc. Announces Plans to Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center

Tue, 22 Sep 2009 16:54:00 0500

HOUSTON-(Business Wire)-September 22, 2009 - Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center...

MagForce Nanotechnologies Completes Patient Recruitment for Pivotal Glioblastoma Study

Tue, 22 Sep 2009 15:53:00 0500

BERLIN-(Business Wire)-September 22, 2009 - MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer^® therapy. The...

United BioSource Consolidates Leadership in Pharmaceutical Risk Management

Tue, 22 Sep 2009 15:32:00 0500

BETHESDA, Md.-(Business Wire)-September 22, 2009 - United BioSource Corporation (UBC) today announced the acquisition of Gigamoto Technology Partners, Inc. (Gigamoto), a Pennsylvania-based software development company providing leading-edge technology solutions in support of drug safety and...

Advanced Cell Completing Pre-Clinical Activities in Preparation for IND Filing

Tue, 22 Sep 2009 15:28:00 0500

WORCESTER, Mass.-(Business Wire)-September 22, 2009 - Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC:

Cardiovascular Systems Reports Two-Year Data Showing Durable Outcomes in Patients Treated with Diamondback 360° Pad System

Tue, 22 Sep 2009 15:00:00 0500

ST. PAUL, Minn. & SAN FRANCISCO-(Business Wire)-September 22, 2009 - Two-year follow-up of patients in the first-ever prospective, multi-center clinical trial evaluating a plaque removal product show promising results after treatment with the Diamondback 360^® PAD System, a...

New Clinical Data on Medtronic Transcatheter Heart Valves Featured in More Than 25 Presentations at TCT 2009

Tue, 22 Sep 2009 15:00:00 0500

MINNEAPOLIS-(Business Wire)-September 22, 2009 - With the promise of percutaneous treatments for patients with diseased heart valves growing, Medtronic, Inc. (NYSE: MDT), announced today that more presentations than ever before – at least 25 – on the company’s portfolio of unique...

Imaging Diagnostic Systems Sells CTLM System in Malaysia

Tue, 22 Sep 2009 13:40:00 0500

FORT LAUDERDALE, Fla.-(Business Wire)-September 22, 2009 - Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) a pioneer in laser optical breast imaging systems, announced today the sale of another CT Laser Mammography system in Asia. The system, which was sold to and installed at the Katherine...

PRA International Names Phase Forward’s OutcomeLogix™ as Preferred Late Phase Solution

Tue, 22 Sep 2009 13:03:00 0500

WALTHAM, Mass.-(Business Wire)-September 22, 2009 - Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced that PRA International has named Phase Forward’s OutcomeLogix™ as its preferred late phase solution...

PHT’s LogPad ePRO System used by Jazz Pharmaceuticals

Tue, 22 Sep 2009 13:00:00 0500

BOSTON-(Business Wire)-September 22, 2009 - PHT Corporation announced that Jazz Pharmaceuticals (Nasdaq: JAZZ...

Curis to Present at Maxim Group Growth Conference 2009

Tue, 22 Sep 2009 12:00:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 22, 2009 - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Maxim Group Growth Conference...

BSD Medical Reports News Briefing at Europe’s Largest Cancer Congress: Hyperthermia and Chemotherapy Treatment Prolongs Survival of Sarcoma Cancer Patients

Tue, 22 Sep 2009 12:00:00 0500

SALT LAKE CITY-(Business Wire)-September 22, 2009 - BSD Medical Corporation (NASDAQ:BSDM) reports that significant and “medical practice changing” clinical study results were the subject of a news briefing at Europe’s largest cancer congress, ECCO15 – ESMO34, which is being held September...

Opexa to Present at the Wall Street Analyst Forum 20th Annual Analyst Conference

Tue, 22 Sep 2009 12:00:00 0500

THE WOODLANDS, Texas-(Business Wire)-September 22, 2009 - Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin^®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s president and chief executive officer, will...

Helicos Presents at Cold Spring Harbor Laboratories Personal Genomes and CHI Next Generation Sequencing Meetings

Tue, 22 Sep 2009 11:30:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 22, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS) provided updates on recent scientific findings and progress on Helicos’s technology initiatives.

Speaking at the Personal Genomes conference in Cold Spring Harbor, NY, and the...

Protalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug

Tue, 22 Sep 2009 11:30:00 0500

CARMIEL, Israel-(Business Wire)-September 22, 2009 - Protalix Biotherapeutics, Inc. (NYSE-Amex: PLX), reported today preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel™). Produced using the Company’s proprietary ProCellEx™ technology, pr-antiTNF is a plant cell...

Celera and Medco Enter Research Collaboration to Evaluate Effect of KIF6 Testing on Compliance with Statin Therapy in Patients with Cardiovascular Disease

Tue, 22 Sep 2009 11:00:00 0500

ALAMEDA, Calif. & FRANKLIN LAKES, N.J.-(Business Wire)-September 22, 2009 - Celera Corporation (NASDAQ:CRA) and Medco Health Solutions, Inc. (NYSE:MHS), today announced that they have entered into a research collaboration to evaluate whether testing for a gene variant called KIF6

Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer’s AROMASIN® (Exemestane Tablets)

Tue, 22 Sep 2009 11:00:00 0500

BERLIN-(Business Wire)-September 22, 2009 - Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the...

Dynavax Announces HEPLISAVTM Data to Be Presented at IDSA Medical Conference

Tue, 22 Sep 2009 10:45:00 0500

BERKELEY, Calif.-(Business Wire)-September 22, 2009 - Dynavax Technologies Corporation (Nasdaq:DVAX) today announced that an abstract with chronic kidney disease patient data for HEPLISAV^TM, an investigational adult hepatitis B vaccine, will be presented at the 47^th Annual...

New England IRB Announces Results of FDA Audit

Mon, 21 Sep 2009 20:37:00 0500

WELLESLEY, Mass.-(Business Wire)-September 21, 2009 - New England IRB is pleased to announce that FDA has sent written notification that the results of their audit conducted in November 2008 indicate no significant findings. No further action is required.

In the current...

Adolor Acquires Rights to Clinical-Stage Product Candidate from Eli Lilly and Company

Mon, 21 Sep 2009 20:30:00 0500

EXTON, Pa.-(Business Wire)-September 21, 2009 - Adolor Corporation (NasdaqGM:ADLR) today announced that it has acquired from Eli Lilly and Company (“Lilly”) the exclusive worldwide rights to OpRA III, a clinical-stage product candidate.

OpRA III is a potent opioid receptor...

Burnham Appoints Michael R. Jackson, Ph.D., Vice President for Drug Discovery & Development

Mon, 21 Sep 2009 20:26:00 0500

LA JOLLA, Calif.-(Business Wire)-September 21, 2009 - Burnham Institute for Medical Research (Burnham) has appointed Michael R. Jackson, Ph.D., to the newly created position of Vice President for Drug Discovery and Development. In this role, Dr. Jackson will oversee the chemical biology and...

Mentor Capital, Inc. Completes 2nd Year Audit for OTCBB Move; Reporting $0.16 Per Share in Basic Earnings

Mon, 21 Sep 2009 19:29:00 0500

SAN DIEGO-(Business Wire)-September 21, 2009 - Mentor Capital, Inc. (Pink Sheets:MNTR) completed its FY 2008 audit in preparation for filing a self-registration statement with the SEC and applying to move from the Pink Sheets to begin being quoted on the Over-the-Counter Bulletin Board system...

Medtronic’s Resolute® Drug-Eluting Stent Maintains Strong, Sustained Efficacy and Safety in Long-Term Follow-up

Mon, 21 Sep 2009 16:00:00 0500

SAN FRANCISCO-(Business Wire)-September 21, 2009 - New clinical data released today at a major meeting of interventional cardiologists show strong and sustained efficacy and safety of the Resolute^® Zotarolimus-Eluting Coronary Stent from Medtronic, Inc. (NYSE: MDT) in long-term...

ENDEAVOR® Stent Reduced Risk of Heart Attack/Cardiac Death by 48% at Three Years Compared to Taxus® Stent in Large Study

Mon, 21 Sep 2009 15:00:00 0500

SAN FRANCISCO-(Business Wire)-September 21, 2009 - Anticipating a change in the practice of interventional cardiology, Medtronic, Inc. (NYSE: MDT), announced today that the latest findings from the ENDEAVOR IV clinical trial – a large study comparing two drug-eluting coronary stents...

In a Tough Economy, Bioscience Research, LLC Helps Eligible Westchester County Residents Access Depression Care at no Cost

Mon, 21 Sep 2009 14:48:00 0500

MOUNT KISCO, N.Y.-(Business Wire)-September 21, 2009 - Psychiatrists at Bioscience Research, LLC, understand the mental health burden that can accompany unemployment and the day-to-day stress of looking for a new job or worrying about losing an existing job. In response to the area’s...

Vitae Initiates Phase 1 Trial of Novel Renin Inhibitor

Mon, 21 Sep 2009 13:00:00 0500

FORT WASHINGTON, Pa.-(Business Wire)-September 21, 2009 - Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999.

VTP-27999 is a novel, proprietary...

Dicerna Pharmaceuticals to Present at 2009 Biologics Drug Delivery & Beyond Conference

Mon, 21 Sep 2009 12:30:00 0500

WATERTOWN, Mass.-(Business Wire)-September 21, 2009 - Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and dicer substrate RNAi molecules, today announced that Sujit K. Basu...

Biogen Idec Commences Tender Offer for Facet Biotech

Mon, 21 Sep 2009 12:15:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 21, 2009 - Biogen Idec Inc. (NASDAQ:BIIB) announced today that FBC Acquisition Corp., its wholly owned subsidiary, has commenced a tender offer to acquire all of the outstanding shares of Facet Biotech Corporation (NASDAQ:FACT) for $14.50 per share in...

Rexahn Pharmaceuticals and Teva Pharmaceutical Industries Close on a License Agreement

Mon, 21 Sep 2009 12:00:00 0500

ROCKVILLE, Md.-(Business Wire)-September 21, 2009 - Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it has closed on its previously announced...

Maxygen Announces Consummation of Joint Venture Transaction With Astellas

Mon, 21 Sep 2009 12:00:00 0500

REDWOOD CITY, Calif.-(Business Wire)-September 21, 2009 - Maxygen, Inc. (Nasdaq:MAXY) today announced the consummation of the transactions contemplated by the previously announced joint venture agreement between Maxygen and Astellas Pharma Inc. Under the joint venture transaction, which closed on...

Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis

Mon, 21 Sep 2009 12:00:00 0500

WILMINGTON, Del.-(Business Wire)-September 21, 2009 - Incyte Corporation (Nasdaq:INCY) announced positive clinical trial results for a topical formulation of its lead janus kinase (JAK) inhibitor, INCB18424, in psoriasis. These results were obtained from a multi-center three-month Phase IIb trial...

PerkinElmer Launches Columbus™ 2.0 High Content Screening Platform for High-Volume Image Data Management and Analysis

Mon, 21 Sep 2009 12:00:00 0500

BOSTON-(Business Wire)-September 21, 2009 - At the High Content Analysis East conference...

Enzo Biochem and National Institutes of Health to Cooperate in Development of Enzo’s Novel Therapeutic Candidate for Treatment of Autoimmune Uveitis

Mon, 21 Sep 2009 11:36:00 0500

NEW YORK-(Business Wire)-September 21, 2009 - Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of...

ARIAD Announces Clinical Data from Phase 1 Study of Its Investigational mTOR Inhibitor, Ridaforolimus, in Combination with Bevacizumab

Mon, 21 Sep 2009 11:35:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 21, 2009 - ARIAD Pharmaceuticals, Inc. (Nasdaq...

Provectus Completes Treatment of All Patients in Phase 2 Trial of PV-10 for Metastatic Melanoma

Mon, 21 Sep 2009 11:30:00 0500

KNOXVILLE, Tenn.-(Business Wire)-September 21, 2009 - Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical...

Data Safety Monitoring Board Recommends Continuation of Celsion’s Phase III ThermoDox® Study for Primary Liver Cancer

Mon, 21 Sep 2009 11:30:00 0500

COLUMBIA, Md.-(Business Wire)-September 21, 2009 - Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board (“DSMB”) has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox® Phase III clinical trial for primary liver cancer...

National Institute of Allergy and Infectious Diseases to Give Update On NIAID-Supported Clinical Trials of 2009 H1N1 Influenza Vaccines in Children Six Months to 17 Years of Age

Mon, 21 Sep 2009 11:00:00 0500

-(Business Wire)-September 21, 2009 - HHS Media Advisory:

Semafore Retains Management Consulting Firm; Names Principal to Key Management Position

Mon, 21 Sep 2009 11:00:00 0500

INDIANAPOLIS-(Business Wire)-September 21, 2009 - Semafore Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other...

Labor Becker-Olgemoeller Selects Bruker´s MALDI Biotyper as an Integrated Multi-Workstation Solution for Microbial Identification

Mon, 21 Sep 2009 05:00:00 0500

GÖTTINGEN, Germany-(Business Wire)-September 21, 2009 - At the 61^st Annual Meeting of the German Society for Hygiene and Microbiology, Bruker Daltonics announces that PHT Corporation and Lionbridge Technologies...

Metabasis Therapeutics Receives Notice of Noncompliance with Nasdaq Listing Requirements

Fri, 18 Sep 2009 20:30:00 0500

SAN DIEGO-(Business Wire)-September 18, 2009 - Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that based upon the...

KCI Sponsors Georgetown Diabetic Limb Salvage Conference Symposium Featuring Top Limb Preservation Experts

Fri, 18 Sep 2009 20:18:00 0500

SAN ANTONIO-(Business Wire)-September 18, 2009 - Kinetic Concepts, Inc. (KCI) will sponsor a CME-accredited panel discussion, “The Role of NPWT in the Team Approach to Limb Salvage: Case Studies,” at the 3^rd Annual Georgetown Diabetic Limb Salvage conference September 24-26. At the...

NovoStent Announces Completion of Enrollment in SAMBA Femoropopliteal Trial

Fri, 18 Sep 2009 18:12:00 0500

MOUNTAIN VIEW, Calif.-(Business Wire)-September 18, 2009 - NovoStent Corporation, a privately held medical device company, today announced the completion of enrollment earlier this summer in the company’s European clinical trial evaluating the use of its SAMBA^TM Stent and Delivery...

Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents

Fri, 18 Sep 2009 17:30:00 0500

NEW YORK-(Business Wire)-September 18, 2009 - Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin^®(exemestane tablets) in a study of early breast cancer,¹ updated study results from a Phase 3 study of...

Hyperion Therapeutics to Present at UBS 2009 Global Life Sciences Conference

Fri, 18 Sep 2009 14:40:00 0500

SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 18, 2009 - Hyperion Therapeutics, Inc. today announced that Donald Santel, Chief Executive Officer, will present at the UBS 2009 Global Life Sciences Conference on Wednesday September 23, 2009 at 4:30 pm ET. The conference will be held at...

FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE® (bortezomib) for Injection

Fri, 18 Sep 2009 14:18:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 18, 2009 - Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall...

BSD Medical Corporation Reports FDA Review of BSD-2000 Hyperthermia System Continues

Fri, 18 Sep 2009 14:15:00 0500

SALT LAKE CITY-(Business Wire)-September 18, 2009 - BSD Medical Corporation (NASDAQ: BSDM) (Pico-Tesla, The...

Dr. Kevin Krenitsky, President of Enzo Clinical Labs, to Present At 27th Annual Lab Institute

Fri, 18 Sep 2009 12:00:00 0500

NEW YORK-(Business Wire)-September 18, 2009 - Enzo Biochem, Inc. (NYSE:ENZ) announced today that Kevin Krenitsky, MD, President of Enzo Clinical Labs, will present at the 27^th Annual Lab Institute ’09, sponsored by Washington G2 Reports, on September 23, 2009 in Arlington...

Array BioPharma Enters into Equity Distribution Agreement

Fri, 18 Sep 2009 12:00:00 0500

BOULDER, Colo.-(Business Wire)-September 18, 2009 - Array BioPharma Inc. (Nasdaq: ARRY) today announced it had entered into an Equity Distribution Agreement with Piper Jaffray & Co. The Equity Distribution Agreement provides that the Company may offer and sell shares of its common stock...

Resolvyx Granted U.S. Patent for the First Resolvin Therapeutic to Enter Human Trials

Fri, 18 Sep 2009 12:00:00 0500

BEDFORD, Mass.-(Business Wire)-September 18, 2009 - Resolvyx Pharmaceuticals, Inc., the leading Resolvin therapeutics company, today announced that the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) covering composition of matter for RX-10045, the first Resolvin...

Clinical Data, Inc. Announces Pharmaceutical Industry Leader Joins the Board of Directors

Fri, 18 Sep 2009 11:30:00 0500

NEWTON, Mass.-(Business Wire)-September 18, 2009 - Clinical Data, Inc. (NASDAQ: CLDA) today announced the...

Pancreatic and Colorectal Cancer Novel Antibody Developed from a Vaccine to Begin Phase I Trial

Thu, 17 Sep 2009 20:28:00 0500

GREAT NECK, N.Y.-(Business Wire)-September 17, 2009 - Neogenix Oncology, Inc. (Neogenix) announced today that NPC-1C, the company’s first IND (Investigational New Drug Application) was granted permission by the Food and Drug Administration (FDA) for the company to begin a Phase I...

Seattle Genetics to Present at UBS Global Life Sciences Conference

Thu, 17 Sep 2009 20:00:00 0500

BOTHELL, Wash.-(Business Wire)-September 17, 2009 - Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present at the 2009 UBS Global Life Sciences Conference on Tuesday, September 22, 2009, at 2:00 p.m. Eastern...

The Bioscience Conference That Thinks Globally

Thu, 17 Sep 2009 19:00:00 0500

COLUMBUS, Ohio-(Business Wire)-September 17, 2009 - On October 1 the 2009 BioOhio Annual Conference, “BioGPS: Global Positioning for Success,” will focus on the globalization of bioscience and the inherent growth opportunities for Ohio organizations. Conference topics will range from...

Hythiam Raises Approximately $7 Million in Registered Direct Offering

Thu, 17 Sep 2009 17:33:00 0500

LOS ANGELES-(Business Wire)-September 17, 2009 - Hythiam, Inc. (NASDAQ:HYTM) announced today that it has entered into definitive agreements to sell 9,333,334 shares of its common stock at a price per share of $.75 to institutional investors pursuant to a registered direct offering...

Meridian Bioscience Granted Special 510(k) Clearance to Add 2009 H1N1 Influenza A Virus Analytical Sensitivity Claim to the TRU FLU® Test Package Insert

Thu, 17 Sep 2009 14:44:00 0500

CINCINNATI-(Business Wire)-September 17, 2009 - Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the company has been granted a Special 510(k) clearance to update the TRU FLU package insert to include analytical sensitivity claims with two strains of 2009 H1N1...

New Essentials Glycemic Health Brand Pasta Launched Using Hi-maize Natural Resistant Starch

Thu, 17 Sep 2009 13:00:00 0500

BRIDGEWATER, N.J.-(Business Wire)-September 17, 2009 - National Starch Food Innovation today announced the launch of a new W. L. Gore & Associates...

Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Hepatic Encephalopathy

Thu, 17 Sep 2009 12:00:00 0500

SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 17, 2009 - Hyperion Therapeutics, Inc. today announced that its investigational product HPN-100 (glycerol phenylbutyrate) has received orphan product designation from the U.S. Food and Drug Administration for intermittent or chronic...

Seaside Therapeutics Secures $30 Million Financing

Thu, 17 Sep 2009 12:00:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 17, 2009 - Seaside Therapeutics LLC today announced that it has secured $30 million in financing from a private, family investment firm which is committed to advancing research in the field of autism and Fragile X Syndrome. The financing will be used...

Juvaris BioTherapeutics Announces First Close on $25 million Series B Financing

Thu, 17 Sep 2009 12:00:00 0500

BURLINGAME, Calif.-(Business Wire)-September 17, 2009 - Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed the first close on its Series B equity financing of up to $25 million led by SV Life Sciences...

RiskMetrics Group – ISS Governance Services Recommends Stockholders Vote “FOR” BioSante and Cell Genesys Merger

Thu, 17 Sep 2009 12:00:00 0500

LINCOLNSHIRE, Ill. & SOUTH SAN FRANCISCO, Calif.-(Business Wire)-September 17, 2009 - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended...

Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Conference

Thu, 17 Sep 2009 12:00:00 0500

ROCKVILLE, Md.-(Business Wire)-September 17, 2009 - Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 2009 UBS Global Life Sciences Conference will be webcast and may be accessed at

Internationally Acclaimed Inventor, Dean Kamen, to Receive Prestigious BioMed SA Palmaz Award for Innovation in Healthcare and the Biosciences

Wed, 16 Sep 2009 15:00:00 0500

SAN ANTONIO-(Business Wire)-September 16, 2009 - Internationally renowned inventor, entrepreneur and thought leader, Dean Kamen of Manchester, NH, can add another prestigious award to his resume when he accepts BioMed SA’s Urovalve

Mentor Capital Cancer Immunotherapy Index Posts Second 20% Plus Monthly Gain Lead by ImmunoCellular Therapeutics

Wed, 16 Sep 2009 13:06:00 0500

SAN DIEGO-(Business Wire)-September 16, 2009 - The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the...

Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

Wed, 16 Sep 2009 13:00:00 0500

CAMBRIDGE, Mass.-(Business Wire)-September 16, 2009 - Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive...

Cyntellect Launches Stem Cell Manager™ Powered by LEAP™

Wed, 16 Sep 2009 13:00:00 0500

SAN DIEGO-(Business Wire)-September 16, 2009 - Cyntellect, Inc., a privately-held life sciences company...

NMT Medical to Accelerate CLOSURE I Data Analysis Timing

Wed, 16 Sep 2009 12:30:00 0500

BOSTON-(Business Wire)-September 16, 2009 - NMT Medical, Inc. (NASDAQ: NMTI) announced today that, upon...

PerkinElmer Purchases GE Healthcare’s Catalog Radiochemicals, SPA Reagents and Cytostar-T Plate Assets

Wed, 16 Sep 2009 12:00:00 0500

WALTHAM, Mass.-(Business Wire)-September 16, 2009 - PerkinElmer, Inc., a global leader focused on improving the health and safety of people and their environment, today announced that it has purchased the assets of GE Healthcare’s ³H and ¹⁴C Catalog Radiochemicals...

Johns Hopkins and National Fibromyalgia Association Announce Successful Outcomes from Landmark Educational Initiative

Wed, 16 Sep 2009 11:30:00 0500

NEW YORK CITY-(Business Wire)-September 16, 2009 - According to The Johns...

Celsion’s ThermoDox® Study for RCW Breast Cancer Aired on ABC and CBS Affiliate Stations

Wed, 16 Sep 2009 11:30:00 0500

COLUMBIA, Md.-(Business Wire)-September 16, 2009 - Celsion Corporation (NASDAQ:CLSN) announced today the Company’s DIGNITY clinical trial evaluating the use of ThermoDox® in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during...

CUSTOMER WIN: Phase Forward to Boost Clinical Trial and Drug Safety Services with BMC Software

Wed, 16 Sep 2009 10:00:00 0500

HOUSTON-(Business Wire)-September 16, 2009 - For many large pharmaceutical and medical device firms, the task of capturing and managing volumes of clinical trial and drug safety data is often outsourced to experts like Phase Forward.

To automate the provisioning, deployment and...

BioClinica™ Acquires Tourtellotte Solutions

Wed, 16 Sep 2009 10:00:00 0500

NEWTOWN, Pa.-(Business Wire)-September 16, 2009 - BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced that it has acquired privately-held Tourtellotte Solutions, Inc. (Tourtellotte), a leader in software and services for the bio-pharmaceutical industry...

Long Beach Memorial Successfully Implants Cutting-Edge Heart Attack Detection Device

Tue, 15 Sep 2009 20:35:00 0500

LONG BEACH, Calif.-(Business Wire)-September 15, 2009 - MemorialCare Heart and Vascular Institute at Long Beach Memorial Medical Center (LBMMC) successfully implanted a new, cutting-edge heart attack detection device in two heart attack survivors this morning. With the danger of a second heart...

PPD Opens Global Central Lab in Singapore

Tue, 15 Sep 2009 20:09:00 0500

WILMINGTON, N.C.-(Business Wire)-September 15, 2009 - PPD, Inc. (Nasdaq: PPDI) today announced it has opened its global central lab facility in Singapore, strengthening its ability to provide biopharmaceutical clients an extensive range of customized laboratory services in Southeast Asia, a...

Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2010 and Reaffirms Fiscal 2009 Guidance

Tue, 15 Sep 2009 20:05:00 0500

CINCINNATI-(Business Wire)-September 15, 2009 - Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2010 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year...

Quintiles Debuts at # 50 in InformationWeek 500

Tue, 15 Sep 2009 16:47:00 0500

RESEARCH TRIANGLE PARK, N.C.-(Business Wire)-September 15, 2009 - Quintiles has been ranked in the 2009 InformationWeek 500, the publication’s annual ranking of the nation’s most innovative users of information technology. Quintiles was ranked 50^th in its first time on the...

Breakthrough Genetic Test Helps Doctors Assess Risk Of Developing Psoriatic Arthritis (PsA)

Tue, 15 Sep 2009 15:12:00 0500

IRVINE, Calif.-(Business Wire)-September 15, 2009 - The first genetic test for Psoriatic arthritis (PsA) is being launched today by NanoBio Corp

STEMCELL Technologies Applauds Feeder-Free Derivation of Human Induced Pluripotent Stem Cells

Mon, 14 Sep 2009 17:26:00 0500

VANCOUVER-(Business Wire)-September 14, 2009 - In a landmark Altair Therapeutics, Inc., a...

BioReference Laboratories, Inc to Speak at the UBS Global Life Sciences Conference

Mon, 14 Sep 2009 12:30:00 0500

ELMWOOD PARK, N.J.-(Business Wire)-September 14, 2009 - BioReference Laboratories, Inc (NASDAQ:BRLI) announced today that Marc D. Grodman M.D., President and Chief Executive Officer, is scheduled to speak at the 2009 UBS Global Life Sciences Conference on Monday, September 21, 2009, at The...

PolyMedix to Make Three Presentations of Antibiotic Data at the 49Th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Mon, 14 Sep 2009 12:30:00 0500

RADNOR, Pa.-(Business Wire)-September 14, 2009 - PolyMedix, Inc. (OTC BB: PYMX,

Digital50.com Clinical Trials News RSS Feed

Penumbra Announces Worldwide Voluntary Field Removal of the Original Version of 6F Neuron 070 Delivery Catheter

Idaho Technology Expands Its High Resolution Melting Patent Portfolio

Celera to Webcast Presentation at JMP Securities 2009 Healthcare Conference

SeraCare Life Sciences Awarded Multiple Contracts from the CDC and NIH to Support HIV Research and the Accuracy of HIV Testing

New Clinical Data Shows AMS’ Minimally Invasive Treatment Options Effective at Restoring Female Pelvic Health

ImThera Medical to Begin European Clinical Trials in Belgium

Luminex Corporation Hosts Seventh Annual Planet xMAP Europe

Bio Japan 2009: The Biggest Biotechnology Event in Japan.

Plexxikon Announces First Patient Dosed in First of Two Pivotal Trials of PLX4032 for Metastatic Melanoma

Sermo Panels Tap into Social Media Platform for On-Demand Physician Opinions

SFC Fluidics, LLC Receives Funding from US Army for Development of Traumatic Brain Injury Diagnostic Device

Cerus to Present Proposal for INTERCEPT Platelet US Phase III Clinical Trial at November BPAC Meeting

BSD Medical Corporation Sells Hyperthermia System to University of California, San Francisco Medical Center

BioClinica™ Showcases Clinical Data Management at SCDM Annual Conference

Flexible Stenting Solutions, Inc. Receives Conditional IDE Approval for FlexStent® Femoropopliteal Self Expanding Stent System

Maxygen Announces Management Changes

Burzynski Research Institute Signs Research Agreement with the University of Alabama at Birmingham (UAB), Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility

International Medica Foundation Starts Phase II Clinical Trial for Rotavirus Vaccine

DiscoveryBioMed, Inc. Awarded Phase 2 SBIR Grant by the NIH to Discover Hypertension and Cystic Fibrosis (CF) Drugs

Savvion and Patni Announce Strategic Partnership

Biomagnetics Diagnostics Receives a Financing Commitment up to $1 Million to Speed Development of Malaria Testing Technology

Ligand and GlaxoSmithKline Collaboration Identifies New Compound

PolyMedix Receives U.S. Patent Protection for Licensed Computational Methods to Design Antimicrobial Polymers

Thommen Medical Announces Chairside Implant Conditioning – North American Premiere at the 2009 AAOMS Meeting in Toronto, Canada

Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin)

Quintiles and Allergan Announce Co-Promotion for Sanctura XR®

Idera Pharmaceuticals Presents Final Data from Phase 2 Clinical Trial of IMO-2055 Monotherapy in Renal Cell Carcinoma

Advaxis Secures $5.0 Million Investment

EnzymeRx Announces Its IND for Uricase-PEG 20 Becomes Effective

Altor BioScience Awarded $3 MM SBIR Bridge Grant by NCI to Advance Clinical Trials for its Targeted Cancer Therapeutic ALT-801

Diabetes Foot Specialists Say Cost-Effective Wound Therapy Underused Due to Healthcare Reimbursement Incentives

Dyax Corp. to Present at the JMP Securities Healthcare Focus Conference

Reverse Medical Corporation Receives FDA IDE Clinical Study Approval for the ReStoreTM Microcatheter

NEVO™ Sirolimus-Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months Than Taxus® Liberte® Stent

Tryton Medical, Inc. Broadcasts Successful Live Case Using Company’s Side-Branch Stent™ to Definitively Treat Bifurcation Lesions at TCT 2009

Advaxis Cures Late Form 10-Q Filing

Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting

Imprime PGG® Named a Top 10 Oncology Drug Candidate for Partnering

Inhibitex Regains Compliance with NASDAQ Listing Requirements

RegeneRx Biopharmaceuticals to Present Several Papers at Second International Symposium on Thymosins in Health and Disease

Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation

BSD Medical Corporation Files $50 Million Shelf Registration

PsoriasisDX and HairDX To Present “Pharmacogenomics In Dermatology And Cosmetics” During EADV Congress

BioPharm America™ 2009 in San Francisco Sets New Benchmark for Partnering Productivity in the US

Two Top Heart Surgeons Join Endovalve, Inc., Scientific Advisory Board

pSivida Anounces New Iluvien® Pilot Study in Patients with Macular Edema Secondary to Retinal Vein Occlusion

KIKA Clinical Solutions Announces Veracity™ 3.7, New Version of Advanced EDC Solution for Clinical Trial Management

First-Ever Controlled Pharmacological Study of ADHD in College Students Launched

Abiomed Reports Results from Academic Medical Center’s Three-Year Follow-up of MACH II Trial

Merck and QIAGEN Collaborate to Accelerate Access to Cervical Cancer Vaccination and Screening in Developing Countries

Genzyme Provides Update on Cerezyme and Fabrazyme Supply

Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress

Humedica’s Next-Generation Clinical Informatics Platform Offers Unparalleled Insight across the Health Care Continuum

Idera Pharmaceuticals Presents Interim Data from Phase 1b Clinical Trial of IMO-2055 in Combination with Tarceva® and Avastin® in Non-Small Cell Lung Cancer

Plexxikon Announces Encouraging Data from Phase 1 Extension Study of PLX4032 Showing Objective Responses in Metastatic Melanoma Patients

BioTime, Inc. to Form Asian Subsidiary

BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger

Transoma Medical Enrolls First Patient in Clinical Study Comparing Use of External Recorders with Implantable Monitors to Track Recurrence of Atrial Fibrillation

Top 20 Pharma Firms to Hunt for Deals at BIO-Europe 2009

Bio-Path Holdings, Inc. Announces Plans to Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center

MagForce Nanotechnologies Completes Patient Recruitment for Pivotal Glioblastoma Study

United BioSource Consolidates Leadership in Pharmaceutical Risk Management

Advanced Cell Completing Pre-Clinical Activities in Preparation for IND Filing

Cardiovascular Systems Reports Two-Year Data Showing Durable Outcomes in Patients Treated with Diamondback 360° Pad System

New Clinical Data on Medtronic Transcatheter Heart Valves Featured in More Than 25 Presentations at TCT 2009

Imaging Diagnostic Systems Sells CTLM System in Malaysia

PRA International Names Phase Forward’s OutcomeLogix™ as Preferred Late Phase Solution

PHT’s LogPad ePRO System used by Jazz Pharmaceuticals

Curis to Present at Maxim Group Growth Conference 2009

BSD Medical Reports News Briefing at Europe’s Largest Cancer Congress: Hyperthermia and Chemotherapy Treatment Prolongs Survival of Sarcoma Cancer Patients

Opexa to Present at the Wall Street Analyst Forum 20th Annual Analyst Conference

Helicos Presents at Cold Spring Harbor Laboratories Personal Genomes and CHI Next Generation Sequencing Meetings

Protalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug

Celera and Medco Enter Research Collaboration to Evaluate Effect of KIF6 Testing on Compliance with Statin Therapy in Patients with Cardiovascular Disease

Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer’s AROMASIN® (Exemestane Tablets)

Dynavax Announces HEPLISAVTM Data to Be Presented at IDSA Medical Conference

New England IRB Announces Results of FDA Audit

Adolor Acquires Rights to Clinical-Stage Product Candidate from Eli Lilly and Company

Burnham Appoints Michael R. Jackson, Ph.D., Vice President for Drug Discovery & Development